Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib in 131I-Refractory Differentiated Thyroid Cancer
NCT02870569Phase 2Completed
- Sponsor
- Zelgen
- Start
- Sep 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of donafenib in differentiated thyroid cancer (DTC) (2 arms), sponsored by Zelgen. Primary endpoint: Objective Response Rate at 24 months. Started Sep 2016; status: completed.
02
Drugs
donafenib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT02870569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870569.